Trial · NCT00576576
Evaluation of Atorvastatin on Atherosclerosis Composition
NCT00576576, Not applicable, Completed, Emory University; results first posted 2013-10-18
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluation of Atorvastatin on Atherosclerosis Composition. Trials, record NCT00576576. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00576576
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluation of Atorvastatin on Atherosclerosis Composition
- NCT number
- NCT00576576
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 27 participants, actual
- Lead sponsor
- Emory University
- Conditions
- Atherosclerosis
- Interventions
- Atorvastatin
- First posted
- 2007-12-19
- Last updated
- 2013-12-24
- Results first posted
- 2013-10-18
- Limitations and caveats
- No adverse events to report.
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Necrotic Core Volume | 6 months | Virtual Histology-Intravascular Ultrasound (VH-IVUS) defined necrotic core cross sectional area (CSA) measured in each VH-IVUS frame and averaged over length of studied vessel at baseline and follow -up. Change in necrotic core CSA between baseline and follow-up was calculated (subtracting the baseline value from the follow-up value). |
| Secondary | Change in Atheroma Volume | 6 months | Change in atheroma volume between baseline and follow-up is reported. This was derived by subtracting the baseline value from the 6-month value. |
| Secondary | Change in Fibrous Plaque Volume | 6 months | Change in fibrous plaque volume between baseline and follow-up. This was derived by subtracting the baseline value from the 6-month value. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Necrotic Core Volume | 6 months | All enrolled patients with complete data set | mm^2 | MEAN |
| SECONDARY | Change in Atheroma Volume | 6 months | All enrolled patients with complete data set | mm^3 | MEDIAN |
| SECONDARY | Change in Fibrous Plaque Volume | 6 months | All enrolled patients with complete data set | mm^3 | MEDIAN |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Necrotic Core Volume | Atorvastatin | 0.07 | Standard Deviation 0.06 | mm^2 | |
| Change in Atheroma Volume | Atorvastatin | -4.0 | Inter-Quartile Range -20.4 to 11.6 | mm^3 | |
| Change in Fibrous Plaque Volume | Atorvastatin | -3.3 | Inter-Quartile Range -15.2 to 8.3 | mm^3 |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Atorvastatin | 27 | |
| Overall Study | COMPLETED | Atorvastatin | 20 | |
| Overall Study | NOT COMPLETED | Atorvastatin | 7 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Atorvastatin | ||
| Total, other adverse events | Atorvastatin | 0 | 27 |
| Total, serious adverse events | Atorvastatin | 0 | 27 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00576576
GET https://conductscience.org/api/trials/v1/NCT00576576/registered